DE-CSC
15.11.2022 15:01:43 CET | Business Wire | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating domain and domain name system (DNS) threats, today released its third annual Domain Security Report that found three out of four Forbes Global 2000 companies have not adopted key domain security measures—exposing them to high risk of security threats. These companies have implemented less than half of all domain security measures.
In addition, lookalike domains are targeting those companies as well—with 75% of homoglyph registrations being registered to unrelated third parties. That means many of the world’s largest brands contend with maliciously registered domains that look like their brands. The intent of these fake domain registrations is to leverage the trust placed on the targeted brand to launch phishing attacks or other forms of digital brand abuse, or IP infringement that leads to revenue loss, traffic diversion, and a diminished brand reputation. Homoglyph domains are just some of the endless domain spoofing tactics and permutations that can be used by phishers and malicious third parties.
Additional key takeaways from CSC’s research include:
-
137 companies (6.8%) had a domain security score of “0”
Not deploying any of the recommended domain security measures puts these companies at risk for a variety of attacks, including but not limited to domain and DNS hijacking attacks, network and data breaches, phishing and ransomware attacks, and business email compromise (BEC).
-
45% of companies that use enterprise-class domain registrars also deploy registry lock
Registry lock is a highly cost-effective means to protect domain names against accidental or unauthorized modifications or deletions. Only 5% of companies that use consumer-grade registrars have registry lock deployed. Additionally, only six organizations within the Global 2000 had the highest overall domain security score, which correlates with their use of an enterprise-class registrar.
-
DMARC is the only domain security measure with significantly increased adoption this year
Given all the news about phishing attacks—including their increase in volume and complexity—it’s no surprise that domain-based message authentication, reporting, and conformance (DMARC) adoption has increased by 12 percentage points in the last 12 months. However, growth in other domain security measures, such as registry lock, domain name system (DNS) redundancy, DNS security extensions (DNSSEC), and certificate authority authorization (CAA) records saw limited increases year-over-year.
“This report shows that while some progress has been made, a majority of the companies listed in the Forbes Global 2000 are still overlooking full implementation of foundational domain security measures,” says Mark Calandra, president of CSC’s Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies that are advocating for a Zero Trust model to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant enterprise risks that can impact their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”
CSC’s report also found that 82% of the third parties registering homoglyph domains are actively masking their identity. This demonstrates the attempt to hide their ownership, showing they may have some nefarious intentions. Additionally, 48% have MX records in 2022, compared to 43% in 2021. MX records can be used to send phishing emails or to intercept email.
To learn more about CSC’s approach to domain security, visit cscdbs.com. Download the Domain Security Report now at cscdbs.com/securityreport.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known cybersecurity oversights that exist, and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss, and significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
